Hans Schreiber to Cancer Vaccines
This is a "connection" page, showing publications Hans Schreiber has written about Cancer Vaccines.
Connection Strength
1.237
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res. 2014 Jan 15; 74(2):632; discussion 635.
Score: 0.430
-
Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
Score: 0.295
-
Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996 May; 47(5):399-407.
Score: 0.126
-
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol. 2014 Feb 01; 192(3):1286-93.
Score: 0.107
-
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug; 1(2):123-33.
Score: 0.104
-
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002 Oct 15; 62(20):5792-9.
Score: 0.049
-
Immunodominance and tumor escape. Semin Cancer Biol. 2002 Feb; 12(1):25-31.
Score: 0.047
-
Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med. 2000 Jun 05; 191(11):1945-56.
Score: 0.042
-
Active immunization against cancer cells: impediments and advances. Semin Oncol. 1998 Dec; 25(6):697-706.
Score: 0.038